课题基金 / 基金详情

MHC-Restricted and MHC-Non-Restricted Targeting of Ovarian Cancer by alphaDC1

MHC-Restricted and MHC-Non-Restricted Targeting of Ovarian Cancer by alphaDC1
alphaDC1 对卵巢癌的 MHC 限制性和 MHC 非限制性靶向
批准号：
8485810
负责人：
Pawel Kalinski
金额：
$25.2万
依托单位：
ROSWELL PARK CANCER INSTITUTE CORP
依托单位国家：
美国
项目类别：
财政年份：
2013
资助国家：
美国
项目状态：
已结题
起止时间：
2013-09-18 至 2018-06-30
来源：
https://reporter.nih.gov/project-details/8485810
关键词：
AntigensAutologous Dendritic CellsCD8B1 geneCD94 AntigenCancer PatientDendritic Cell VaccineEpitopesGenomic InstabilityGoalsImmuneImmunosuppressionImmunotherapyInfusion proceduresMalignant NeoplasmsMalignant neoplasm of ovaryMutatePatientsRecurrenceResidual TumorsT-LymphocyteUniversity of Pittsburgh Cancer InstituteVariantcancer cellchemotherapyneoplastic cellnoveloutcome forecastpreventtumor

项目摘要

项目成果

Pawel Kalinski的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Genomic instability of ovarian cancer (OvCa) cells and the resulting frequent loss or reduction of HLA expression and function facilitate immune avoidance of this aggressive cancer. The goal of this Project is to develop an effective mode of immunotherapy capable of targeting both MHC-positive and MHC-negative variants of OvCa and counteracting local immune suppression, known to contribute to poor prognosis in OvCa patients. We observed that type-1-polarized DCs (¿DC1s), a novel type of DCs developed by our group, effectively cross-present OvCa-related antigens and induce high numbers of MHC class l-restricted CTLs capable of recognizing defined OvCa-related antigenic epitopes. However aDC1-induced CTLs also express elevated levels of NK receptors, NKG2D- and DNAM1. Such
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Targeting the Chemokine System to Sensitize Tumors to Immunotherapy
Core A: Administrative Core
Project 1: Combinatorial adjuvants promote uniform and selective intratumoral CTL infiltration in colorectal cancer
IRP-3
海外基金